CA1002938A - Steroids, processes for their manufacture and preparations containing same - Google Patents

Steroids, processes for their manufacture and preparations containing same

Info

Publication number
CA1002938A
CA1002938A CA171,785A CA171785A CA1002938A CA 1002938 A CA1002938 A CA 1002938A CA 171785 A CA171785 A CA 171785A CA 1002938 A CA1002938 A CA 1002938A
Authority
CA
Canada
Prior art keywords
steroids
manufacture
processes
preparations containing
containing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA171,785A
Other languages
English (en)
Other versions
CA171785S (en
Inventor
Ralph L. Brattsand
Karl G. Claeson
Bo T. Af Ekenstam
Bror A. Thalen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saab Bofors AB
Original Assignee
Bofors AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20269234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1002938(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bofors AB filed Critical Bofors AB
Application granted granted Critical
Publication of CA1002938A publication Critical patent/CA1002938A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA171,785A 1972-05-19 1973-05-18 Steroids, processes for their manufacture and preparations containing same Expired CA1002938A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (enExample) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
CA1002938A true CA1002938A (en) 1977-01-04

Family

ID=20269234

Family Applications (1)

Application Number Title Priority Date Filing Date
CA171,785A Expired CA1002938A (en) 1972-05-19 1973-05-18 Steroids, processes for their manufacture and preparations containing same

Country Status (26)

Country Link
US (2) US3929768A (enExample)
JP (1) JPS5521760B2 (enExample)
AT (1) AT328630B (enExample)
BE (1) BE799727A (enExample)
CA (1) CA1002938A (enExample)
CH (1) CH595400A5 (enExample)
CS (1) CS178129B2 (enExample)
CY (1) CY1013A (enExample)
DD (1) DD104295A5 (enExample)
DE (1) DE2323215C3 (enExample)
DK (1) DK134783B (enExample)
ES (1) ES414673A1 (enExample)
FI (1) FI50631C (enExample)
FR (1) FR2185405B1 (enExample)
GB (1) GB1429922A (enExample)
HK (1) HK49179A (enExample)
HU (1) HU166680B (enExample)
IL (1) IL42155A (enExample)
KE (1) KE2970A (enExample)
NL (2) NL177493C (enExample)
NO (2) NO139640C (enExample)
PL (1) PL87765B1 (enExample)
SE (1) SE378109B (enExample)
SU (1) SU470954A3 (enExample)
YU (1) YU35896B (enExample)
ZA (1) ZA732955B (enExample)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8403905D0 (sv) * 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
SE8501693D0 (sv) * 1985-04-04 1985-04-04 Draco Ab Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8506015D0 (sv) * 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
LV5274A3 (lv) * 1988-02-29 1993-10-10 Richter Gedeon Vegyeszet 22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
HU203769B (en) * 1989-03-09 1991-09-30 Richter Gedeon Vegyeszet Process for producing new steroide derivatives and pharmaceutical compositions containing them
SE8903219D0 (sv) * 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
MD24C2 (ro) * 1991-07-09 1994-05-31 Fabrica De Parfumerii Si Cosmetica "Viorica" Compoziţie de substanţe odorante
LT3695B (en) 1991-11-18 1996-02-26 Dineika Raimundas Arnas Folded roof
SK282826B6 (sk) * 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
CA2149777C (en) * 1992-12-24 2004-05-25 Michael John Ashton New steroids
RU95115547A (ru) * 1993-01-08 1997-06-10 Астра Актиеболаг (SE) Стероидные соединения, способы их получения и фармацевтический препарат
CN1062869C (zh) 1993-04-02 2001-03-07 比克·古尔顿·劳姆贝尔格化学公司 新型脱氢皮质醇衍生物
GB9423919D0 (en) * 1994-11-26 1995-01-11 Rhone Poulenc Rorer Ltd Chemical process
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
AU2003291634A1 (en) * 2002-10-08 2004-05-04 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
MXPA05011225A (es) * 2003-04-18 2005-12-14 Pharmacia & Upjohn Co Llc Politerapias.
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AR045536A1 (es) * 2003-08-29 2005-11-02 Ranbaxy Lab Ltd Inhibidores de la fosfodiesterasa tipo -iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
WO2005100356A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP1948167A1 (en) * 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Compositions of phosphodiesterase type iv inhibitors
RU2008119323A (ru) 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
EP1869064A2 (en) * 2005-11-02 2007-12-26 Sicor, Inc. Improved process for the preparation of ciclesonide
AR059216A1 (es) 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
NZ574905A (en) 2006-08-22 2011-12-22 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
JP2010504323A (ja) * 2006-09-22 2010-02-12 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害物質
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674084C (en) 2006-12-26 2013-05-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
EP1958639A1 (en) 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
SI2124944T1 (sl) * 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090082319A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched budesonide
WO2009045539A2 (en) * 2007-10-05 2009-04-09 Nektar Therapeutics Al, Corporation Oligomer-corticosteroid conjugates
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2262823B1 (en) * 2008-03-13 2013-01-23 Farmabios S.p.A. Process for the preparation of pregnane derivatives
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CN101279997B (zh) * 2008-05-29 2011-08-24 鲁南制药集团股份有限公司 布地奈德的一种制备方法
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SI3106149T1 (sl) 2009-05-29 2020-07-31 Pearl Therapeutics, Inc. Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
CN106421797A (zh) 2009-10-01 2017-02-22 艾戴尔医药公司 口服给予的皮质类固醇组合物
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011093812A2 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
JP2013518909A (ja) 2010-02-08 2013-05-23 キナゲン，インク． アロステリックキナーゼ阻害が関係する治療方法および組成物
CN101863952B (zh) * 2010-04-30 2013-04-17 湖北葛店人福药业有限责任公司 布地奈德的制备方法
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
RU2609833C2 (ru) 2011-09-13 2017-02-06 Фармасайкликс Элэлси Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013109214A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Process for the preparation of dry powder formulations
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN103421075B (zh) * 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
JP6453218B2 (ja) 2012-08-24 2019-01-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 疾患を治療するためのｈｉｆ活性の複素環式修飾物質
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
HK1219059A1 (zh) 2013-03-15 2017-03-24 珍珠治疗公司 用於微粒晶体材料的状态调节的方法和系统
WO2014190204A1 (en) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3250211B1 (en) 2015-01-30 2021-12-22 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
KR20190074310A (ko) 2016-11-08 2019-06-27 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
CA3063871A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
JP7426931B2 (ja) 2017-11-07 2024-02-02 レゲネロン ファーマシューティカルス，インコーポレーテッド 抗体薬物コンジュゲートのための親水性リンカー
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
BR112020013492A2 (pt) 2018-01-08 2020-12-08 Regeneron Pharmaceuticals, Inc. Esteroides e conjugados de anticorpo dos mesmos
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
ES2981514T3 (es) 2021-07-09 2024-10-09 Astrazeneca Pharmaceuticals Lp Composiciones, métodos y sistemas para el suministro de fármacos en aerosol
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
GEAP202516720A (en) 2022-09-02 2025-07-10 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
IL320396A (en) 2022-10-25 2025-06-01 Merck Sharp & Dohme Llc Charge-linkers of anti-drug conjugates derived from extacan, pharmaceutical compositions, and uses thereof
US20240207425A1 (en) 2022-12-14 2024-06-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US2990401A (en) * 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae
JPS4843910A (enExample) * 1971-10-08 1973-06-25

Also Published As

Publication number Publication date
IL42155A0 (en) 1973-07-30
NL930025I1 (nl) 1993-06-01
DE2323215A1 (de) 1973-11-29
GB1429922A (en) 1976-03-31
NO1994013I1 (no) 1994-08-31
KE2970A (en) 1979-07-20
NO139640B (no) 1979-01-08
JPS5521760B2 (enExample) 1980-06-12
CY1013A (en) 1979-11-23
DK134783B (da) 1977-01-17
IL42155A (en) 1977-06-30
US3983233A (en) 1976-09-28
ZA732955B (en) 1974-04-24
CH595400A5 (enExample) 1978-02-15
NL7306978A (enExample) 1973-11-21
FR2185405A1 (enExample) 1974-01-04
CS178129B2 (enExample) 1977-08-31
DE2323215C3 (de) 1978-03-30
US3929768A (en) 1975-12-30
NL177493C (nl) 1985-10-01
SE378109B (enExample) 1975-08-18
AT328630B (de) 1976-03-25
AU5525373A (en) 1974-11-07
DK134783C (enExample) 1977-06-06
HU166680B (enExample) 1975-05-28
FR2185405B1 (enExample) 1976-12-31
JPS4941378A (enExample) 1974-04-18
NL177493B (nl) 1985-05-01
DD104295A5 (enExample) 1974-03-05
PL87765B1 (enExample) 1976-07-31
YU129173A (en) 1981-02-28
ES414673A1 (es) 1976-07-01
DE2323215B2 (de) 1977-08-11
YU35896B (en) 1981-08-31
FI50631C (fi) 1976-05-10
BE799727A (fr) 1973-09-17
ATA436573A (de) 1975-06-15
NO139640C (no) 1979-04-18
FI50631B (enExample) 1976-02-02
SU470954A3 (ru) 1975-05-15
HK49179A (en) 1979-07-27

Similar Documents

Publication Publication Date Title
CA1002938A (en) Steroids, processes for their manufacture and preparations containing same
AU470393B2 (en) N-benzhydryl-n-p-hydroxbenzyl-piperazines and processes for their manufacture
AU474345B2 (en) Benzenesulfonyl-ureas and processes for preparing them
CA1020546A (en) 21-sulfinyl steroids
CA1018976A (en) Perfluoroalkylaminoalkanols, process for their manufacture and their use
AU467625B2 (en) New amino-propane derivatives and processes for their preparation
AU487812B2 (en) New Steroids, processes for their manufacture and preparations containing same
CA1026334A (en) Nitroimidazolyl-triazolo-pyridazines and process for their preparation
AU473635B2 (en) Anhydrofuranose derivatives and processes for their manufacture
CA906136A (en) Copolyamideimine and copolyamidebenzimidazole, and processes for their preparation
CA1030974A (en) Oxabicyclononanes and process for their manufacture
CA902623A (en) N-acyl-p-dialkylaminophenylhydrazones and processes for their preparation
CA853205A (en) Azabicycloaliphatic compounds, process for their manufacture and preparations containing them
CA907249A (en) Polyarylether-sulphones and processes for their manufacture
CA899850A (en) 11.beta.-HALOGENATED STEROIDS AND PROCESSES FOR THEIR PREPARATION
CA896539A (en) 3-aza-19-hydroxy-3,19-cyclo-a-homosteroids and process for their manufacture
CA895264A (en) Polyisocyanate-impregnated, paper-overlaid panel and process for making same
CA910300A (en) Gona-4,9-dien-3-ones and process
CA904267A (en) Oestratriol and process for its manufacture
CA891486A (en) A-furan steroids
CA892018A (en) 6-gem-difluoro steroids
AU485903B2 (en) 2-2-dimethyl steroids
CA895284A (en) Steroids
CA1002939A (en) Steroids
CA903192A (en) Processes for preparing 16-unsaturated steroids